Adding platinum to neoadjuvant chemotherapy has been proved to increase the pCR rate in TNBC patients and the accompanying adverse effect is tolerable and manageable although the benefit of overall survival has not been well-established.

This lecture aims to present the efficacy and safety of various neoadjuvant regimens for patients diagnosed with early stage or locally advanced triple-negative breast cancer (TNBC).